CEL-SCI Corp (CVM)

0.12
0.00 1.57
AMEX : Health Care
Prev Close 0.13
Open 0.13
Day Low/High 0.12 / 0.14
52 Wk Low/High 0.36 / 0.80
Volume 3.08M
Avg Volume 2.30M
Exchange AMEX
Shares Outstanding 188.72M
Market Cap 24.53M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CEL-SCI Reports Fiscal 2016 Financial Results And Clinical & Corporate Developments

CEL-SCI Reports Fiscal 2016 Financial Results And Clinical & Corporate Developments

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") reported financial results today for the fiscal year ended September 30, 2016.

CEL-SCI Reports On NYSE MKT Noncompliance Notice And Compliance Plan

CEL-SCI Reports On NYSE MKT Noncompliance Notice And Compliance Plan

CEL-SCI Corporation (NYSE MKT: CVM) reported on a communication received today from the staff of the NYSE MKT, its current listing exchange, that it considered the Company to be noncompliant with certain listing...

CEL-SCI Announces Pricing Of $4.25 Million Public Offering Of Common Stock And Warrants

CEL-SCI Announces Pricing Of $4.25 Million Public Offering Of Common Stock And Warrants

CEL-SCI Corporation (NYSE MKT:CVM) announced today that it has priced its public offering of common stock and warrants.

CEL-SCI Announces Proposed Public Offering Of Common Stock And Warrants

CEL-SCI Announces Proposed Public Offering Of Common Stock And Warrants

CEL-SCI Corporation (NYSE MKT: CVM) announced today that it intends to offer and sell, subject to market and other conditions shares of its common stock and warrants to purchase common stock.

CEL-SCI Submits Response To FDA In Connection With Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Submits Response To FDA In Connection With Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Corporation (NYSE MKT:CVM) announced today that it has submitted its response to the U.

CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis

CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis

CEL-SCI Corporation (NYSE MKT: CVM), a biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, today announced new...

CEL-SCI Provides Update On Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Provides Update On Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Corporation (NYSE MKT:CVM) announced today: following up on our press release issued on September 26, 2016, we have received the Partial Clinical Hold letter from the U.

CEL-SCI Reports Clinical Hold On Head And Neck Cancer Study

CEL-SCI Reports Clinical Hold On Head And Neck Cancer Study

CEL-SCI Corporation (NYSE MKT:CVM) announced today that it has received verbal notice from the U.

IIROC Trading Resumption - CVM

IIROC Trading Resumption - CVM

CEL-SCI Announces Resignation Of Its Founder For Health Reasons

CEL-SCI Announces Resignation Of Its Founder For Health Reasons

CEL-SCI Corporation (NYSE MKT:CVM) today announced that its founder, President and Chairman of the Board, Maximilian de Clara has resigned for personal health reasons, effective immediately.

CEL-SCI Reports Monthly Patient Enrollment In August For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In August For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of August it has enrolled 28 patients in its ongoing Phase 3 trial of its investigational immunotherapy...

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT: CVM) announced that it has closed its previously announced registered direct offering with institutional investors.

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT:CVM) today announced it has entered into a definitive agreement with institutional investors to purchase approximately 10 million shares of its common stock and warrants exercisable for up to...

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) reported financial results for the quarter ended June 30, 2016 and updates shareholders in regards to the upcoming date for the Company's arbitration hearing against its former Clinical...

CEL-SCI Reports Monthly Patient Enrollment In July For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In July For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT:CVM) ("CEL SCI" or the "Company") today announced that during the month of July it has enrolled 29 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Granted European Patent For Multikine Cancer Immunotherapy In Combination With Radiation And/or Chemotherapy

CEL-SCI Granted European Patent For Multikine Cancer Immunotherapy In Combination With Radiation And/or Chemotherapy

CEL-SCI Corporation ( NYSE MKT: CVM ) announces that it has been granted a new European patent covering its investigational Phase 3 cancer immunotherapy drug Multikine* (Leucocyte Interleukin).

CEL-SCI Reports Monthly Patient Enrollment In June For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In June For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of June it has enrolled 32 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Reports Monthly Patient Enrollment In May For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In May For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of May it has enrolled 19 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI To Present At The Fifth Annual Marcum MicroCap Conference

CEL-SCI To Present At The Fifth Annual Marcum MicroCap Conference

CEL-SCI Corporation (NYSE MKT: CVM), a late-stage cancer immunotherapy company, announced today that it will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City...

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has closed its previously announced registered direct offering with a single healthcare dedicated institutional investor.

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT: CVM) today announced it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase approximately 10 million shares of its common stock and...

CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2016.

CEL-SCI Reports Record Monthly Patient Enrollment In April For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Record Monthly Patient Enrollment In April For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT:CVM) ("CEL SCI" or the "Company") today announced that during the month of April it has enrolled 41 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Featured On The RedChip Money Report Airing On Newsmax TV

CEL-SCI Featured On The RedChip Money Report Airing On Newsmax TV

CEL-SCI Corporation (NYSE MKT:CVM) announced today that its CEO, Geert Kersten, was recently interviewed on The RedChip Money Report television program.

CEL-SCI Reports Monthly Patient Enrollment In March For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In March For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of March it has enrolled 32 patients in its ongoing Phase 3 trial of its investigational immunotherapy...

CEL-SCI Reports Monthly Patient Enrollment In February For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In February For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of February it has enrolled 27 patients in its ongoing Phase 3 trial of its investigational immunotherapy...

CEO Geert Kersten Summarizes CEL-SCI's Phase 3 Cancer Immunotherapy Progress In A New Video Interview

CEO Geert Kersten Summarizes CEL-SCI's Phase 3 Cancer Immunotherapy Progress In A New Video Interview

CEL-SCI Corporation (NYSE MKT:CVM) announced today that a new video interview with Geert Kersten, Chief Executive Officer, is available for viewing.

CEL-SCI CEO Geert Kersten Was A Featured Guest On Fox Business' Making Money With Charles Payne

CEL-SCI CEO Geert Kersten Was A Featured Guest On Fox Business' Making Money With Charles Payne

CEL-SCI Corporation (NYSE MKT:CVM) announced today that its Chief Executive Officer Geert Kersten was a guest on Fox Business' Making Money with Charles Payne.